The LIT Sunday News

De-escalation and the Damage Done: Lower Tariffs, Lingering Risks

Tariff Reduction Brings Relief — For Now

President Donald Trump’s decision to reduce tariffs on Chinese goods from 145% to 30% for 90 days, while China drops its own from 125% to 10%, marks a dramatic pivot in trade tensions. This partial rollback, which effectively ends a short-lived embargo on many Chinese imports, was cheered by markets. But analysts warn that economic and investor risks remain elevated, and any relief may be fleeting.

Trump’s Tactical Retreat: The “TACO” Pattern

• TACO = Trump Always Chickens Out: Analysts note a recurring pattern in Trump's policy cycle — aggressive announcement → backlash → rapid retreat.

• January to March 2025: Escalating tariffs across Canada, Mexico, and China were announced, signed, and implemented — only to be walked back.

• April-May 2025: The extreme global tariff regime is again softened, with Trump signaling flexibility under pressure.

This “two steps forward, one step back” tactic still causes market damage, even if many of the worst-case scenarios are reversed.

Remaining Risks and Structural Damage

1. Investor Confusion & Market Volatility

• The unpredictability of US trade policy has led to foreign capital flight and dollar weakness.

• A $200bn effective tax increase from tariffs could shave 4-5% off US corporate profits, with little reflection in current earnings estimates.

2. Foreign Rebalancing

• Global pension funds and insurance companies are under pressure to reduce unhedged dollar exposure due to heightened volatility.

• European equity markets are benefiting as money managers seek regional diversification amid uncertainty in US policymaking.

3. Supply Chain Friction

• Firms are reacting defensively to Trump’s reversals, frontloading imports in anticipation of further changes.

• The 90-day tariff pause may temporarily ease disruption, but persistent uncertainty could permanently degrade supply chain reliability.

4. Fed Policy Still Constrained

• Despite the de-escalation, the Federal Reserve is unlikely to cut rates soon, facing sticky inflation and strong employment data.

• The temporary nature of the tariff relief fails to provide the long-term clarity needed for dovish monetary policy.

Long-Term Implications

• Inflation hedge rethink: Treasury bonds may no longer offer the reliable protection they once did amid unstable trade policy and higher structural inflation.

• Business planning anxiety: Corporate strategists must now incorporate political volatility as a baseline risk, undermining long-term investment confidence.

• Global trust erosion: Allies and trading partners are learning to treat US commitments as transient, weakening America's influence in setting global economic norms.

TL;DR

Trump’s tariff rollback on China (145% → 30%) has calmed markets, but the economic damage lingers. Supply chains remain strained, foreign investors are reducing US exposure, and the Federal Reserve still won’t cut rates. Despite recurring retreats, Trump’s erratic trade strategy has sown deep uncertainty, and “backing off” isn’t the same as restoring confidence. The scars of unpredictability may last far longer than any tariff.

America’s Food Insecurity Crisis: A Strategic Wake-Up Call

America’s Growing Food Trade Deficit

The United States — once the world’s agricultural powerhouse — is rapidly becoming dependent on imported food. In 2024, the U.S. ran a record $38 billion agricultural trade deficit, which is forecast to balloon to $49 billion in 2025. While the country still exports grain and soybeans, it imports the majority of its fruit, vegetables, seafood and even meat. The long-promised benefits of trade liberalization have disproportionately favored global agribusiness giants, while gutting small and midsized family farms.

• Since 1997, the U.S. has lost over 312,000 farms and 63 million acres of farmland.

• 60% of fresh fruit consumed in the U.S. is now imported — double the share from the early 1980s.

• Core export commodities like corn and wheat have shown decades of stagnation, while deficits in meat, fruit and vegetables continue to climb.

The Myth of Export Growth

While agricultural exports have increased in dollar terms, this growth is largely illusory when adjusted for inflation and commodity price volatility. Volume growth has been negligible, particularly for key staples:

• Corn exports: Up only 4.1% since 1995, despite 40% global population growth.

• Wheat exports: Down 33% in volume since 1995.

The real winners? Multinational agribusiness firms that dominate bulk grain and oilseed trade, masking the erosion of U.S. leadership in diverse food production.

A National Security Threat in Disguise

Dependence on food imports is more than an economic issue — it’s a strategic vulnerability:

• Global supply chain disruptions from wars, pandemics, or cyberattacks could threaten access to essential food.

• FDA oversight of imported foods is minimal; most shipments are not inspected before hitting store shelves.

• Loss of local farms erodes rural economies, undermines community resilience, and reduces food freshness and quality.

Imported food is optimized for shelf life, not nutrition — and Americans pay the price in health and transparency.

How Big Ag Wrote the Rules

The current trade model privileges a few export-friendly crops — corn, soy, wheat — while outsourcing everything else. Big Ag lobbyists have shaped policy to favor industrial monoculture and consolidation, driving out smaller producers and diminishing local food diversity. The result is a food system that works for corporations, not communities.

• In 2024, the U.S. had a $12 billion deficit in fruit, $11 billion in meat and seafood, and $5 billion in vegetables.

• Farmers are squeezed out, while cheap, low-inspection imports flood the shelves.

A Call for Action: Use Section 232

The article argues that it's time for the federal government to invoke Section 232 of the Trade Expansion Act — a legal tool previously used to protect critical industries like steel — to:

• Investigate the national security implications of food imports.

• Support U.S. farmers by curbing unfair import competition.

• Promote fresh, local, and nutritious food systems over cheap, commoditized global alternatives.

TL;DR

America’s dependence on food imports has become a national security crisis, driven by decades of flawed trade policy and agribusiness consolidation. With millions of acres of farmland lost and deficits in nearly every major food category, the U.S. is more vulnerable than ever to global shocks. A Section 232 investigation could reset the balance — restoring resilience, supporting local farmers, and reasserting food sovereignty. Because food isn’t just a commodity — it’s a pillar of national security.

US-China Tariff Truce Triggers Early Holiday Stockpiling Surge

Retailers Race to Beat August Tariff Deadline

Following the 90-day US-China trade ceasefire announced on May 13, US retailers are accelerating orders for Black Friday and Christmas goods to take advantage of temporarily reduced tariffs. The headline rate on Chinese imports drops from 145% to 30% until August 10, creating a narrow window for importers to save on costs — and avoid potential future disruption.

• Normal seasonal imports for the holiday period (July–October) are now being pulled forward into May and June.

• This has created a "whipsaw" effect — a collapse in April bookings followed by an anticipated surge in shipments through June and July.

Ports and Shipping Brace for Volume Shock

Shipping experts and logistics providers warn that the sudden rush to import goods will strain supply chains, potentially resulting in:

• Equipment shortages and tight vessel capacity.

• Delays at ports in both China and the US.

• Rising container rates, though likely not as high as in 2024.

Key statistics:

• Almost 400,000 fewer containers than planned were booked from Asia to North America between May 5 and June.

• US container import volumes from China are still expected to be down 20% YoY from June to September, but this could be softened by the truce-induced pull-forward.

Uncertainty Still Shadows Trade Flow

Despite the ceasefire, analysts caution that:

• A 30% tariff is still historically high, making the incentive to front-load weaker than in past tariff cycles.

• The 90-day window is short, and the risk of reversion to higher tariffs in August tempers optimism.

• Businesses had already stockpiled heavily in late 2024 and early 2025, with import volumes up 11% YoY from November to April, potentially easing current urgency.

Revolution Beauty, for instance, confirmed it pre-shipped “significant volumes” to US warehouses and is now cautiously resuming new shipments.

TL;DR

The 90-day tariff truce between the US and China is reshaping global shipping patterns, as US retailers rush to import holiday merchandise before August 10. Expect a short-term spike in freight demand, potential port delays, and modest container price hikes. But with tariffs still elevated and only temporarily paused, the long-term uncertainty remains, and the race to restock may prove both chaotic and costly.

Nvidia Plans Shanghai R&D Hub Amid Tight US Export Controls

Strategic Investment in Chinese AI Market

Nvidia is planning to open a new research and development centre in Shanghai, reaffirming its long-term commitment to China despite intensifying US export restrictions. The move is designed to help tailor products to Chinese customer needs, safeguard Nvidia’s market share, and retain access to China’s AI talent pool.

• CEO Jensen Huang discussed the project with Shanghai mayor Gong Zheng last month.

• The facility will focus on product optimisation, autonomous driving, and chip verification, without violating US export rules.

• Nvidia explicitly stated it would not transfer GPU designs to China for modification, adhering to Washington’s legal limits.

Navigating US-China Trade Tensions

While Nvidia’s high-end AI chips like the H100 and H20 are now restricted, the company is pursuing limited workarounds, including:

• Selling lower-performance L20 chips to Chinese clients.

• Maintaining operations with around 2,000 employees in Shanghai, mainly in sales and support.

• Lobbying the US government to avoid losing critical commercial access in China.

But challenges remain:

• Major clients like ByteDance, Alibaba and Tencent are wary of relying on downgraded US chips.

• Some are evaluating full transitions to Chinese AI chip ecosystems like those powered by Huawei, risking Nvidia’s dominance.

AI Talent & Market Opportunity

Huang emphasised that retaining access to China’s AI engineers is vital to Nvidia’s global competitiveness. Recruitment ads for Shanghai roles point to ambitions in next-generation deep learning, ASIC design, and global AI hardware development.

Despite US sales restrictions, Huang believes China could become a $50bn market for Nvidia — up from $17bn last year — if access is preserved. “If we leave a market altogether, there’s no question somebody else would step in. Huawei... is very formidable,” he said recently.

TL;DR

Nvidia is pushing ahead with plans for a Shanghai-based R&D centre, betting on China’s long-term value despite headwinds from US export controls. While the facility will focus on legal, lower-risk technical work and help retain Chinese AI talent, Nvidia’s grip on the market faces threats from Huawei-led domestic competition and regulatory uncertainty in Washington. The company’s future in China now hinges on striking a delicate geopolitical and commercial balance.

Baidu Eyes Europe for Robotaxi Expansion Amid Global Self-Driving Race

Strategic Push into Europe

Baidu, China’s largest autonomous vehicle operator, is actively negotiating to launch robotaxi trials in Europe, with Switzerland and Turkey as its initial targets. This move marks a major step in Baidu’s ambition to export its Apollo Go self-driving platform globally and capitalize on growing interest in autonomous mobility.

• The company has held talks with Swiss officials, including preliminary discussions with the national postal service (Swiss Post), though no formal partnership has been established.

• Baidu aims to establish a European office in Switzerland and begin testing robotaxis before the end of 2025

Industry Context and Competitor Moves

Baidu is joining a broader wave of Chinese autonomous vehicle (AV) companies pushing into international markets:

• WeRide is trialling robobuses in France and Switzerland.

• Pony.ai received a robotaxi testing permit in Luxembourg.

• Uber signed agreements with WeRide, Pony.ai, and Momenta to integrate their AV fleets across Europe and the Middle East.

Baidu’s expansion strategy is “asset-light”, focused on partnering with local taxi and fleet operators, aligning with comments from CEO Robin Li about 2025 being a “paramount year” for global growth.

Strategic Implications & Regulatory Backdrop

The autonomous vehicle space has become a techno-geopolitical battleground:

• Chinese firms are perceived as technological frontrunners due to aggressive government backing, broad urban test zones, and faster deployment cycles.

• The US has flagged national security concerns over Chinese-connected vehicle software and lidar providers like Hesai, which is now on a Pentagon blacklist.

Despite these concerns, Chinese companies are expanding where regulatory environments are more open, such as Europe and parts of Asia.

Market Outlook & Safety Concerns

• Baidu’s Apollo Go provided 1.1 million rides in Q4 2024, reaching a cumulative total of over 9 million rides by January 2025.

• Goldman Sachs forecasts the global robotaxi market to grow from $54mn in 2025 to $47bn by 2030, with Chinese operators expected to dominate due to data and algorithmic advantages.

• Still, safety remains a key issue. A recent fire in a Pony.ai robotaxi in Beijing, though without injuries, raised concerns on social media and within the industry.

TL;DR

Baidu is preparing to launch robotaxi trials in Switzerland and Turkey as part of its global expansion strategy. As the robotaxi market surges, Baidu and its Chinese peers — WeRide, Pony.ai — are pushing into Europe, where regulatory climates are more favorable than in the US. While Baidu leads in cumulative rides and R&D, success abroad will depend on managing geopolitical sensitivities and addressing safety concerns in the rapidly evolving autonomous vehicle sector.

How Hims & Hers Defied the SPAC Collapse – But the Real Test Lies Ahead

Surviving the SPAC Crash

Hims & Hers Health has become a standout among the 2021 class of SPAC mergers, escaping the fate of most peers. While 92% of SPACs now trade below their launch price, Hims & Hers has quintupled in value since merging with an Oaktree Capital-backed SPAC. In contrast, companies like Playboy — which announced a SPAC merger the same day — have shed nearly 90% of their value.

GLP-1 Gold Rush

The company’s biggest breakout moment came with its launch of compounded semaglutide in May 2024. By selling a $199/month version of Wegovy's active ingredient, it positioned itself as a low-cost, accessible alternative to Novo Nordisk’s and Eli Lilly’s high-priced weight-loss drugs. This led to:

• 69% revenue growth to $1.5bn in 2024

• First annual profit

• Share price surge, as investors bet on demand for cheaper GLP-1 drugs

However, this model hit a wall when the FDA declared the shortages resolved in early 2025, making compounded versions no longer permissible. Hims’ stock subsequently plunged.

Pivoting to a Brand-Name Strategy

Rather than retreat, Hims struck a distribution deal with Novo Nordisk to sell Wegovy legitimately on its platform. It now expects:

• 2025 revenue of $2.3bn–$2.4bn (+63% YoY)

• A 2030 target of $6.5bn in annual revenue (implying ~22% CAGR from 2026 onward)

However, challenges remain:

• Price resistance: Hims’ core customer base, drawn in by sub-$200 compounded drugs, may be reluctant to adopt full-price, brand-name GLP-1s

• Rising competition: Telehealth rivals like Ro and LifeMD have also secured Wegovy distribution deals

Strategic Outlook: Beyond GLP-1

To hit its long-term growth targets, Hims & Hers will need to:

• Cross-sell existing products like skincare, hair loss, and mental health treatments to new weight-loss subscribers

• Expand its direct-to-consumer platform while preserving its low-cost, accessible brand image

• Continue leveraging its agile product development and marketing model, which helped it outperform in a volatile SPAC environment

TL;DR

Hims & Hers is one of the few SPAC-era winners, driven largely by early success with compounded weight-loss drugs. While the FDA’s ruling ended that edge, its new partnership with Novo Nordisk and ambitions for $6.5bn in revenue by 2030 signal confidence. But the company must now prove it can thrive in a competitive, full-price GLP-1 market — and convert those customers into long-term subscribers across its broader health portfolio.

UnitedHealth Turmoil Deepens as CEO Witty Resigns Amid Profit Cuts and Regulatory Pressure

Leadership Crisis at UnitedHealth

UnitedHealth Group, the largest US health insurer by revenue, announced on Tuesday that CEO Andrew Witty has stepped down effective immediately, citing “personal reasons.” His departure comes during a period of intense turbulence for the company, which also suspended its 2025 guidance. The board has reinstated former CEO Stephen Hemsley to the role.

• Witty, who joined in 2021, leaves as the company faces mounting financial and regulatory challenges.

• Hemsley, CEO from 2006 to 2017, will now reassume operational control while remaining board chair.

UnitedHealth shares plunged 17.8%, closing at their lowest level since October 2020.

Mounting Challenges

Witty’s exit follows several crises:

• Profit warnings: In April, UnitedHealth slashed its annual profit forecast due to unexpectedly high demand for medical services among older patients and lower reimbursement policies enacted under the Biden administration.

• Leadership trauma: The murder of Brian Thompson, CEO of UnitedHealth’s insurance division, added internal instability.

• Regulatory scrutiny: The company is now facing: An antitrust investigation into its dominant market position. Criticism of coverage practices and regulatory questions around its pharmacy benefits operations.

Morningstar noted a “murky outlook” and said the executive turnover “injects more uncertainty into the situation.”

Trump Administration Policy Pressure

The leadership change coincides with Donald Trump’s push to reduce drug prices, which includes:

• Encouraging direct-to-consumer drug sales to bypass pharmacy benefit managers (PBMs).

• UnitedHealth’s OptumRx division is one of the largest PBMs in the US, potentially making it a target of these reforms.

Trump’s policy remarks also sent shares of other PBM-exposed companies, including Cigna and CVS, sharply lower on Monday.

TL;DR

UnitedHealth is in a leadership and regulatory crisis. CEO Andrew Witty has resigned unexpectedly amid profit warnings, antitrust investigations, and rising healthcare utilization. Former CEO Stephen Hemsley returns as the company faces uncertainty, compounded by Trump’s new push to undercut intermediaries in drug pricing — a direct threat to UnitedHealth’s PBM business. Investors responded sharply, sending the stock down nearly 18%.

Moët Hennessy in Crisis: Price Hikes, Dubious Deals and Strategic Missteps Trigger Cash Burn and Restructuring

Overview

Moët Hennessy, the iconic wine and spirits division of LVMH, is undergoing a deep crisis marked by plunging profits, mounting losses, and an aggressive overhaul of its leadership and strategy. Once a reliable cash generator, the group has swung from generating €1bn in cash in 2019 to burning €1.5bn in 2024, driven by collapsing sales, overpriced acquisitions, and unsustainable pricing tactics.

Key Developments

• Severe Downturn in Performance
  Moët Hennessy's organic sales fell 9% in Q1 2025, while profits from recurring operations dropped 36% last year. Margins sank to 23%, well below the 30% internal target.

• Leadership Overhaul
  Philippe Schaus, CEO since 2017, exited at the start of 2025 after overseeing an era of aggressive expansion. Former LVMH CFO Jean-Jacques Guiony now leads Moët Hennessy, with Alexandre Arnault (son of Bernard Arnault) as his deputy.
  
  

• Job Cuts and Restructuring
  Approximately 1,200 jobs — 10% of the workforce — will be cut. Management has warned staff not to expect a quick rebound.

Strategic Missteps

• Price Inflation Backfires
  Double-digit price increases in 2021 and 2022 across the portfolio lifted average prices over one-third higher since 2019. Retailers began resisting, and volume declines overwhelmed any margin protection.

• Failed M&A Spree
  Nearly €2bn spent on acquisitions under Schaus — including: 50% of Jay-Z’s Armand de Brignac champagne (sourced by Alexandre Arnault), Minuty rosé brand, Joseph Phelps Vineyards, Volcan tequila and Eminente Cuban rum.
  Many have underperformed, with some described as having "added complexity, lowered margin and drained cash."

• Loss-Making Direct-to-Consumer Push
  The pivot into DTC — with luxury brand outlets and e-commerce initiatives like Tannico (jointly launched with Campari) — is losing millions annually and now under full review.

New Leadership's Approach

• Portfolio Review Underway
  Guiony has stated that growth plans for underperforming brands will be scaled back and costs cut sharply. Alexandre Arnault is reviewing private sales and the direct retail strategy.

• Acknowledgement of Strategic Overreach
  Guiony admitted to staff that efforts to scale across multiple geographies simultaneously were a mistake, signaling a return to focused, performance-driven execution.

Internal Pressures and LVMH’s Demands

• Despite deteriorating performance, LVMH leadership refused to lower profit targets, pressuring Moët Hennessy to find ways to plug a €90mn shortfall.

• Internal communications from Schaus show managers were directed to “rise to the challenge” rather than revise down expectations.

TL;DR

Moët Hennessy is undergoing a major crisis amid collapsing profits, failed acquisitions, inflated pricing, and strategic overreach under ex-CEO Schaus. Now led by Jean-Jacques Guiony and Alexandre Arnault, the LVMH unit is undergoing deep restructuring, job cuts, and a portfolio reset. With margins squeezed and retailers balking at price hikes, the once-bulletproof luxury drinks business must rebuild under intense internal pressure — and in the shadow of Bernard Arnault’s demands for growth at all costs.

Tesla Considers New Pay Deal for Elon Musk Amid Legal Setbacks and Investor Tensions

Special Committee Formed

Tesla's board has formed a special committee comprising chair Robyn Denholm and director Kathleen Wilson-Thompson to explore a new compensation package for Elon Musk, amid ongoing legal battles over his historic 2018 pay plan and growing investor unease. The committee is also evaluating potential alternative compensation avenues should Tesla fail to reinstate the 2018 package through its ongoing appeal to the Delaware Supreme Court.

The 2018 Package in Limbo

• Musk’s original 2018 deal, once valued at up to $146bn, was struck down in early 2024 by a Delaware judge for being excessive and improperly approved by a conflicted board.

• Despite a shareholder vote in June 2024 to reapprove the package, Chancellor Kathaleen McCormick dismissed that effort, citing board members' undue deference to Musk.

• Musk was awarded 304 million stock options after hitting performance milestones, but legal validation of those options is now uncertain.

New Compensation in Development

• A new package, still in early stages, could involve stock options tied to stringent financial, operational, and share price targets.

• If reinstated, Musk's ownership would increase from 13% to over 20%.

• Discussions are influenced by Musk’s threat to leave Tesla unless he gains more control, citing the need for at least 25% ownership to “fend off activists” and ensure Tesla’s AI strategy aligns with his vision.

Legal and Financial Hurdles

• Tesla’s move to incorporate in Texas—partly in protest against the Delaware ruling—means any new deal must comply with Texas corporate law. Tesla has now engaged McDermott Will & Emery, a firm specializing in Texan governance.

• If the board simply reissues the old options, it could trigger a $50bn accounting charge and a 57% tax hit for Musk, due to the options being “in the money” already.

Investor and Governance Pressures

• Shareholders are being actively consulted, with growing concerns about Tesla's leadership stability amid weak EV sales and political entanglements.

• Directors themselves have faced scrutiny: several agreed to return $900mn to settle claims of excessive compensation. Denholm alone has sold $538mn in Tesla shares since 2014.

Political Complications and Business Impact

• Musk’s dual role in Trump’s administration and his controversial leadership of X (formerly Twitter) have made him a political lightning rod.

• Tesla has struggled with slumping EV demand and geopolitical headwinds, notably in China and Europe, exacerbated by Trump’s tariffs.

• In an attempt to reassure investors, Musk recently pledged to refocus on Tesla and has increased his physical presence in Austin HQ.

Outlook

The special committee’s work comes at a delicate time, with Tesla’s annual shareholder meeting likely delayed, allowing more time for resolution. Tesla stock has rallied modestly since Musk’s renewed commitment to the company but remains 32% below its December 2024 peak.

TL;DR

Tesla’s board is weighing a new pay package for Elon Musk amid a protracted legal fight over his $56bn 2018 compensation. A special committee is exploring options under Texas law, following Tesla’s corporate relocation from Delaware. With Musk demanding more control and threatening to leave, and Tesla battling regulatory, political, and financial turmoil, the board must balance governance scrutiny with retaining its high-profile CEO.